Chair’s summary and audience Q&A.

27 August 2017 (13:40 - 13:45)

Organised by:

About the speaker

Professor Nikolaus Marx

RWTH University Hospital Aachen, Aachen (Germany)

6 More presentations in this session

Presentation thumbnail

Introduction – Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?

Professor N. Marx (Aachen, DE)

Presentation thumbnail

Managing cardiovascular outcomes in patients with type 2 diabetes – Where have we come from and where are we going?

Professor D. McGuire (Dallas, US)

Presentation thumbnail

Cardiovascular risk reduction with empagliflozin: exploring the evidence from EMPA-REG OUTCOME®.

Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Presentation thumbnail

Using empagliflozin in your patients with type 2 diabetes: considerations for daily patient care.

Doctor J. Udell (Toronto, CA)

Presentation thumbnail

Experience with empagliflozin: insights from practice.

Professor N. Marx (Aachen, DE) Professor F. Zannad (Vandoeuvre-Les-Nancy, FR) Professor D. McGuire (Dallas, US) Doctor J. Udell (Toronto, CA)

Access the full session

Session thumbnail

Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?

The Event

ESC Congress 2017

27 August 2017 13:40 CET

You may be interested in

Congress Session

Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

27 August 2023

Congress Session

Treatment of cardiovascular comorbidities in patients with heart failure

17 May 2025

Webinar

EAPC Webinar: Type 2 Diabetes and cardiovascular risk

12 March 2019

Congress Presentation

Summary.

29 August 2022

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources